ABSTRACT
OBJECTIVE: To investigate the application effect of oncolytic herpes simplex virus Once Vex(GM-CSF) and adriamycin in malignant tumor. METHODS: A total of 102 cases of malignant tumor were analyzed retrospectively from April 2013 to April 2015 of Cancer Treatment Center of Affiliated Hospital of Beihua University, and these cases were randomly divided into trial group (n=51) and control group (n=51). The control group was treated with adriamycin and the trial group patients received conditionally replicating adenoviruses on the basis of the control group.The adenovirus proliferation was analyzed via quantitative PCR to investigate the malignant tumor cell inhibitory action in two groups. RESULTS: Treatment group total effective rate (96.1%, 49/51) was significantly higher than the control group (78.4%, 40/51) (χ(2)=7.845, P=0.014). There were statistically significant difference of the killing capability between trial group (86.3%, 44/51) and control group (23.5%, 12/51) (χ(2)=7.859, P=0.013). Tumor shrinkage rate of trial group(76.5%, 39/51) was superior to that of the control group(19.6%, 10/51), the difference was statistically significant (χ(2)=7.654, P=0.019). There was statistically significant difference of the decrease of tumor marker CA125 between trial group (74.5%, 38/51) and control group (23.5%, 12/51) (χ(2)=7.342, P=0.023). CONCLUSION: Once Vex(GM-CSF) can effectively kill the tumor cells in the treatment of malignant tumor, and shrink the tumor significantly.
